
Specialist drugs trial solicitors Alexander Harris,who represents the two most seriously affected victims of the Northwick Park clinical drug trial condemned the report released today by the Medicines and Healthcare products Regulatory Body (MHRA).
They said it was "totally inadequate."
Alexander Harris called for an independent Inquiry into the conduct of the trial and a wholesale review into the MHRA who she described as an "insular organisation with an archaic approach."
"This disaster was bound to happen. We believe that the self regulation of this organisation was not appropriate for such complex scientific administration," said Alexander Harris .
Alexander Harris stressed: "Today's report is a whitewash and leaves very many questions unanswered. It gives no detailed information about the pre-clinical trials, about which there has been conflicting information since the trial was suspended. Were the animals involved appropriate for a comparison with human subjects? What were the effects on these animals? We question the reports findings that the reaction was unpredictable, and we call for independent scrutiny of these and many more questions raised but not answered, by the report."
They continued: "We also demand answers to the questions raised by the manner in which the human trials themselves were conducted. We have now had access to evidence that suggests that the human subjects were not treated for up to 5 hours after the first symptoms were reported. We also want answers to when the trial was suspended by Parexel in order for the Hospital to take over and treat the symptoms displayed horrifically by the subjects."
"The report also affirms that the type of drugs being tested was a new class of monoclonal antibody, and with such new drugs we question why the subjects were given the drug at a gap of only 10 minutes, and not a longer period which would have saved at least a couple of the subjects from suffering as they undoubtedly did."
"Why did the MHRA not seek any outside expert opinion before they conducted this new and dangerous procedure?
"My clients and the general public are entitled to answers to these questions."
"We note with interest the conclusions of last year's Health Select Committee report on the influence of the Pharmaceutical Industry. It found a lack of transparency in the MHRA and complained that there was no public access to data. It also concluded that there was a "major failing in the regulatory system" and drew attention to the fact that theMHRA is "entirely funded by fees from those it regulates".
"The concerns of the Select Committee seem to have been confirmed by the MHRA's investigations. I now have little faith in the MHRA's ability to seek, obtain or make public detailed and relevant information about the clinical history of this trial or the manner in which it was conducted. I believe that an independent Inquiry is now essential," said Alexander Harris .
BackRelated news stories
- 25/07/2006: Expert Scientific Group (ESG), chaired by Professor Gordon Duff publishes interim report on safety of clinical drug trials
- 24/07/2006: TGN1412 clinical drug trial - Gordon Duff report published
- 05/07/2006: Northwick Park clinical drug trials - drug manufacturer Tegenero file for insolvency
- 23/03/2006: Clinical drug trials - leading clinical negligence solicitor explains
- 15/03/2006: Drug Trials - volunteers suffer multiple organ failure
If you believe that you might have a legal claim relating to this story, please complete the online enquiry form or call 0870 024 0558. Your enquiry will be forwarded to a solicitor who specialises in this area.
If you have any comments in relation to this story, please use the online discussion forum.
This news section contains stories of interest to our clients from publicly available news sources. Where we are representing the clients referred to in the news material we will say so. Where we do not represent individuals or bodies mentioned or quoted, the inclusion of the news story in our news section is not intended nor should it be taken to imply that we act for the individual or body concerned.
